Slide 1: Orion Interim Report 1−9/2022
Orion Interim Report 1−9/2022
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January−September 2022
Highlights in January−September 2022
Slide 4: An eventful year for Orion so far
An eventful year for Orion so far Bayer updated estimate on Nubeqa’s peak Acquisition of animal health company VMD sales potential (Inovet) Research focus on oncology and pain Orion and MSD announced a global development and commercialisation agreement for ODM-208 Liisa Hurme appointed as President
Slide 5: Sales developed well – milestone having material impact on net sales and operating profit
Sales developed well – milestone having material impact on net sales and operating profit Orion • Orion and MSD announced a global development and commercialisation agreement for ODM-208 - Upfront payment of USD 290 million of which EUR 228 million recognized in Q3 2022 net sales and operating profi
Slide 6: Key figures 1−9/2022 – upfront payment impacts all figures
Key figures 1−9/2022 – upfront payment impacts all figures Net sales Operating profit Operating profit Cash flow from margin operating activities per share 1,046 399 38% 3.05 MEUR (765) MEUR (203) (27%) EUR (0.99) +37% +96% +208% Interim Report 1−9/2022 © Orion Corporation 20 October 2022 6
Slide 7: Development of net sales in 1−9/2022 vs. 1−9/2021
Development of net sales in 1−9/2022 vs. 1−9/2021 231 1,046 20 11 11 3 765 -21 27 * Nubeqa® product sales & royalty ** Proprietary Products and Specialty Products *** Animal Health, Fermion and Contract Manufacturing **** Without Nubeqa® royalties The figures in the chart are rounded, which is why t
Slide 8: Development of operating profit in 1−9/2022 vs. 1−9/2021
Development of operating profit in 1−9/2022 vs. 1−9/2021 236 -57 -45 -2 45 399 18 203 * Product & service sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mix change but without exchange rate effec
Slide 9: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1−9/2022 1−9/2021 1−9/2022 10% 23% 350 +13% +372% 300 +3% 298 299 250 263 29% 200 230 237 MEUR 10% -1% +5% 150 100 105 104 102 107 28% 50 63 Finland Scandinavia 0 Other Europe North America RoW RoW = Rest of the World Interim Report 1−9/2022 © Orio
Slide 10: Animal Health growing strongly due to Inovet acquisition
Animal Health growing strongly due to Inovet acquisition 1−9/2021 1−9/2022 1−9/2022 600 +85% 5% 1% 500 530 +5% 6% 400 368 386 MEUR 300 51% 287 37% 200 +23% -4% +592% 100 Proprietary Products 53 65 55 53 2 11 0 Specialty Products Specialty Proprietary Animal Health Fermion & Other* Animal Health Prod
Slide 11: TOP 10 products in 1−9/2022
TOP 10 products in 1−9/2022 EUR million vs. 1−9/2021 1. Easyhaler® product portfolio 94 +13% 2. Stalevo®, Comtess®, Comtan® 79 +7% 3. Nubeqa® 53 +101% 4. Simdax® 33 -22% 5. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 28 +6% 6. Divina® series 20 +19% 7. Burana® 19 +14% 8. Solomet® 18 +15% 9. dexdor
Slide 12: Proprietary Products
Proprietary Products GRION Building well-being
Slide 13: Nubeqa® and ODM-208 milestone driving the growth
Nubeqa® and ODM-208 milestone driving the growth Proprietary Products sales split 1−9/2022 +650% +13% 256 15% +7% 94 48% 83 79 +101% MEUR 74 -22% 18% 53 -44% 43 33 34 3% 26 27 15 6% 10% Easyhaler® Parkinson's Nubeqa® Simdax® Dexdor® Others* portfolio franchise Parkinson's Easyhaler® Dexdor® Simdax®
Slide 14: Nubeqa® sales booked by Orion showing strong growth
Nubeqa® sales* booked by Orion showing strong growth – vary as expected from quarter to quarter 25 +101% 20 53 15 MEUR 10 MEUR 5 26 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 YTD9'21 YTD9'22 Royalty Product sales to Bayer * Orion’s sales to Bayer for commercial use + royalties from
Slide 15: Easyhaler® continued on a growth path (+13%)
Easyhaler® continued on a growth path (+13%) 40 35 60 30 52 25 MEUR 20 MEUR +14% 15 10 5 31 34 0 +11% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 YTD9'21 YTD9'22 Other Budesonide-formoterol Easyhaler® Interim Report 1−9/2022 © Orion Corporation 20 October 2022 15
Slide 16: Sales of Parkinson's franchise +7%
Sales of Parkinson's franchise +7% 40 35 30 79 25 74 MEUR 20 MEUR 15 +7% 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 YTD9'21 YTD9'22 2019 2020 2021 2022 Interim Report 1−9/2022 © Orion Corporation 20 October 2022 16
Slide 17: Dexdor® and Simdax® - declining as expected
Dexdor® and Simdax® - declining as expected Dexdor® Simdax® 20 -44% 20 -22% 15 27 15 43 MEUR MEUR 10 10 33 MEUR MEUR 15 5 5 0 0 YTD9'21YTD9'22 YTD9'21YTD9'22 2019 2020 2021 2022 2019 2020 2021 2022 Interim Report 1−9/2022 © Orion Corporation 20 October 2022 17
Slide 18: Specialty Products
Specialty Products GRION Building well-being
Slide 19: Geographical split of net sales
Geographical split of net sales Sales split 1−9/2022 250 +3% 15% 200 202 209 150 16% MEUR 100 +1% +3% +20% 54% 50 57 58 61 62 57 48 15% 0 Finland Scandinavia Eastern RoW Finland Europe Scandinavia Eastern Europe 1−9/2021 1−9/2022 Rest of the World (RoW) Interim Report 1−9/2022 © Orion Corporation 20
Slide 20: Growth in both product segments
Growth in both product segments +3% Sales split 1−9/2022 300 276 283 250 27% 200 MEUR 150 +12% 100 92 103 50 0 73% Generic Self Care prescription drugs products Generic drugs Self-care products 1−9/2021 1−9/2022 Interim Report 1−9/2022 © Orion Corporation 20 October 2022 20
Slide 21: In Finland, Orion's reference priced prescription drugs developed clearly better than the market
In Finland, Orion’s reference priced prescription drugs developed clearly better than the market The market for reference priced The sales of Orion's reference prescription drugs in Finland* priced prescription drugs in (1−9/2022) Finland MEUR 330 (353) MEUR 80 (72) Market development Orion’s develo
Slide 22: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−9/2022 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 2,254 million (+4%) prescription Orion market share in drugs pharmacy 300 Orion market share in 250 242 pharm
Slide 23: Research and development
Research and development Interim Report 1−9/2022 © Orion Corporation 20 October 2022
Slide 24: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication Phase I Phase II Phase III Registration ARASENS / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III Registration ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ODM-208 2 Prostate cancer (mCRPC)
Slide 25: Orion and responsibility
Orion and responsibility Building well-being
Slide 26: Energy risk management in Orion
Energy risk management in Orion Orion is targeting carbon neutrality in its own operations by 2030 Systematic progress towards 2030 carbon neutrality target. For the short term, emissions may increase and the share of renewable energy may decrease. Ensuring the availability of energy for own product
Slide 27: Business targets and outlook
Business targets and outlook
Slide 28: Focus areas in 2022
Focus areas in 2022 Status on 30 TARGET KPIs 2022 September 2022 Increasing the sales of Significant increase in sales of Nubeqa® booked by Orion the current product portfolio Easyhaler® product portfolio sales increase by more than 5% In-licensing of new products Portfolio enhancement through produ
Slide 29: Outlook for 2022
Outlook for 2022 (published on 13 July 2022) Orion estimates that in 2022 net sales will be Net sales clearly higher than in 2021 (in 2021 net sales were EUR 1,041 million). Operating profit is estimated to be Operating clearly higher than in 2021 profit (in 2021 operating profit was EUR 243 million
Slide 30: Key assumptions impacting the outlook
Key assumptions impacting the outlook Operating Net sales profit + Upfront + Upfront payment payment + Nubeqa® + Nubeqa® - Simdax® + VMD acquisition - dexdor® - Simdax® - Cost inflation - dexdor® - Price competition in generics - Sales & marketing expenses Interim Report 1−9/2022 © Orion Corporation
Slide 31: Upcoming events
Upcoming events Financial Statement Release for 2022 9/2/2023 AGM planned to be held 22/3/2023 Interim Report 1-3/2023 27/4/2023 Half-Year Financial Report 17/7/2023 Interim Report 1-9/2023 26/10/2023
Slide 32: Building well-being
Building well-being GRIoN Building well-being
Slide 33: Appendix
Appendix GRIoN Building well-being
Slide 34: Net sales and operating profit by quarter (MEUR)
Net sales and operating profit by quarter (MEUR) Net sales Operating profit 600 300 500 250 400 200 300 150 200 100 100 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Interim Report 1−9/2022 © Orion Corporation 20 October 2022 34
Slide 35: Quarterly net sales by unit (MEUR)
Quarterly net sales by unit (MEUR) Proprietary Products Specialty Products 150 300 200 100 100 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Animal Health Fermion & Contract Manufacturing 40 30 20 20 10 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2018 2019